Share This Page
Drug Price Trends for INTELENCE
✉ Email this page to a colleague
Average Pharmacy Cost for INTELENCE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| INTELENCE 200 MG TABLET | 59676-0571-01 | 24.25754 | EACH | 2025-11-19 |
| INTELENCE 200 MG TABLET | 59676-0571-01 | 24.26585 | EACH | 2025-10-22 |
| INTELENCE 200 MG TABLET | 59676-0571-01 | 24.25754 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Intelence (Etravirine)
Introduction
Intelence (Etravirine), marketed by Janssen Pharmaceuticals, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed for the treatment of HIV-1 infection. Approved by the U.S. Food and Drug Administration (FDA) in 2008, Intelence is primarily employed in treatment-experienced patients with resistant HIV strains, often in combination with other antiretrovirals (ARVs). The drug has carved out a niche within the complex HIV therapeutic landscape; however, its market dynamics and pricing trajectory are influenced by evolving HIV treatment paradigms, patent landscapes, and competitive alternatives.
This analysis evaluates Intelence’s current market landscape, examines competitive and regulatory factors, and provides price projection insights for the upcoming years.
Market Landscape Analysis
Global and Regional Market Overview
The global HIV therapeutics market was valued at approximately USD 25 billion in 2022, with projections surpassing USD 33 billion by 2030, driven by increased diagnosis, treatment access expansion, and the rise of combination regimens (Exact figures from [1]).
Intelence occupies a specialized segment within the NNRTI class, primarily targeting treatment-experienced patients harboring resistant strains. Its revenue contribution remains modest compared to first-line NNRTIs like Efavirenz and newer agents such as Doravirine, which have expanded options for initial therapy.
Across North America and Europe, the drug maintains a niche due to its efficacy in resistant cases but faces competition from newer agents with improved safety profiles and simplified dosing.
Key Market Drivers
- Treatment-Resistant HIV Population: The persistence of drug-resistant HIV strains sustains the need for Intelence, especially in salvage therapy regimens.
- Clinical Evidence & Guidelines: Inclusion in treatment guidelines supports ongoing demand, although newer agents' emergence modifies its positioning.
- Patented Status & Patent Expirations: As of 2023, Intelence’s patent protection extends until 2025 in the U.S. and Europe, after which generic competitors are anticipated to enter the market.
Competitive Landscape
- Emerging and Existing Alternatives: Next-generation NNRTIs such as Doravirine and Rilpivirine present improved tolerability, lower pill burden, and fewer drug-drug interactions.
- Integrase inhibitors' dominance: The shift toward integrase strand transfer inhibitors (InSTIs) for first-line treatment (e.g., Dolutegravir, Bictegravir) indirectly impacts Intelence's market share, confining it largely to salvage therapy.
Regulatory and Patent Risks
Patent expiration poses a significant risk, which is expected in 2025, opening the door for generic competition. Development of biosimilars and competitors could exert downward pressure on prices from mid-decade.
Pricing Analysis
Historical Pricing Trends
In the United States, Intelence's list price averages around USD 2,300–2,800 per month, translating to approximately USD 27,600–33,600 annually per patient ([2]). These prices are consistent with other niche antiretrovirals.
Rebates, insurance negotiations, and patient assistance programs influence net prices, often resulting in substantial discounts. Nevertheless, manufacturer list prices serve as benchmarks for economic assessments.
Current Pricing Factors
- Demand Dynamics: Limited to treatment-experienced, resistant cases.
- Market Competition: Competing agents’ newer formulations and safety profiles reduce pricing power.
- Regulatory Pressures: Insurance and Medicaid formularies increasingly favor generics or newer agents, exerting further downward pressure on prices.
Price Projection Outlook (2023–2030)
Anticipated price trends hinge primarily on patent expiry, competitive dynamics, and evolving treatment guidelines:
| Year | Expected Price Trend | Rationale |
|---|---|---|
| 2023–2024 | Stable | Patent protection maintains pricing; demand remains stable within niche segment. |
| 2025 | Sharp decline | Patent expiration allows generic entry, leading to substantial price reductions (~30–50%). |
| 2026–2028 | Market-driven decline | Increased generics, biosimilars, and pressure from newer agents continue downward pricing. Prices could fall 50–70% relative to peak levels. |
| 2029–2030 | Stabilization or slight decline | Market saturation and patent cliff effects stabilize prices, likely remaining 60–80% lower than peak values. |
This projections assume no new formulations or indications. Should Janssen develop combinations or extended claims, pricing could be somewhat stabilized through added clinical value.
Market Opportunities and Challenges
Opportunities:
- Post-Patent Generic Entry: Significant revenue erosion is likely post-2025 but peut incentivize aggressive market strategies or licensee partnerships elsewhere.
- Development of Biosimilars or Fixed-Dose Combinations: Potential to rejuvenate market interest and command premium pricing for combination pills.
- Emerging Markets: As HIV prevalence rates surge, particularly in African and Asian regions, affordable generic versions may expand usage, broadening market access.
Challenges:
- Competitive Emergence: The swift transition towards InSTI-based first-line therapies limits expansion into new treatment cohorts.
- Pricing Pressure: Payers and governmental agencies push for cost-effective alternatives, especially as patents expire.
- Clinical Positioning: Etravirine’s niche status restricts volume scalability compared to broader-spectrum ARVs.
Key Takeaways
- Market Position: Intelence remains a critical salvage therapy agent for resistant HIV infections but faces structural challenges due to patent expiration and shifting treatment paradigms.
- Pricing Trends: High current list prices are expected to decline sharply following patent expiry in 2025, with reductions potentially exceeding 60% in subsequent years.
- Strategic Outlook: Janssen’s ability to leverage patent protections until 2025 will sustain revenues in the near term. Post-expiry, market share will depend on the quality and pricing of generics, alongside the emergence of innovative therapies.
- Competitive Dynamics: Transitioning to InSTIs and newer NNRTIs constrains long-term growth prospects; however, availability of biosimilars and combination therapies may create new opportunities.
- Market Expansion: Growth in resource-limited settings could maintain demand for affordable generics, albeit with lower profit margins.
FAQs
1. When is Intelence's patent expected to expire?
Intelence's primary patents are set to expire around 2025 in the U.S. and Europe, paving the way for generic competition.
2. How does Intelence compare to newer NNRTIs and InSTIs?
While Intelence remains effective for resistant HIV strains, newer agents like Doravirine offer improved safety and dosing profiles, leading to reduced reliance on Intelence for initial therapy.
3. What is the potential impact of generic entry on Intelence's price?
Generic entry could lead to price reductions of 50–70% within 1–2 years post-patent expiry, significantly affecting revenue.
4. Are there any ongoing efforts to extend Intelence’s patent protection?
No publicized efforts are underway; patent expiration is expected to happen as scheduled, shifting focus to biosimilars and alternative formulations.
5. How might emerging therapies influence Intelence’s market share?
Advancements in HIV treatment, particularly the adoption of InSTIs and combination regimens, are likely to further confine Intelence’s market to niche, treatment-experienced segments.
References
[1] IQVIA Reports, “Global HIV Therapeutics Market Outlook,” 2022.
[2] FDA Drug Data, “Intelence (Etravirine) Pricing and Sales Data,” 2023.
More… ↓
